Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

RecruitingOBSERVATIONAL
Enrollment

260

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Interventions
DRUG

Trastuzumab deruxtecan (T-DXd)

This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd (starting dose 6.4 mg/kg IV Q3W) will be enrolled in this study as part of clinical routine or the clinical judgement of physician.

Trial Locations (36)

100029

RECRUITING

China-Japan Friendship Hospital, Beijing

100032

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

100034

RECRUITING

Peking University First Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

110000

NOT_YET_RECRUITING

Liaoning Cancer Hospital, Shenyang

130031

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

200003

RECRUITING

Shanghai GoBroad Cancer Hospital, Shanghai

200011

NOT_YET_RECRUITING

Shanghai ninth People's Hospital,Shanghai Jiaotong University School of Medicine, Shanghai

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

200032

RECRUITING

Zhongshan Hospital, Shanghai

201104

RECRUITING

Huadong Hospital Affiliated to Fudan University, Shanghai

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

210009

NOT_YET_RECRUITING

Jiangsu Cancer Hospital, Nanjing

221006

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

236000

RECRUITING

Anhui Province Cancer Hoospital, Hefei

300000

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

300211

NOT_YET_RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

310005

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

310009

NOT_YET_RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

317700

RECRUITING

Taizhou Hospital of Zhejiang Province, Taizhou

350000

RECRUITING

Fujian Cancer Hospital, Fuzhou

361003

NOT_YET_RECRUITING

The Affiliated Hospital of Xiamen University, Xiamen

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

450066

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510095

RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

510120

RECRUITING

Guangdong Hospital of Traditional Chinese Medicine, Guangzhou

515000

RECRUITING

Cancer Hospital of Shantou University Medical College, Shantou

529000

RECRUITING

Jiangmen Central Hospital, Jiangmen

570100

RECRUITING

Hainan General Hospital, Haikou

710061

RECRUITING

The Affiliated Hospital of Xi'an Jiaotong University, Xi'an

046000

RECRUITING

Changzhi People's Hospital, Changzhi

030000

RECRUITING

Shanxi Cancer Hospital, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY